HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences, Inc. HOOKIPA completed and delivered a regulatory support package for Gilead’s Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using HOOKIPA’s arenaviral platform. The first participant in the Phase 1 clinical trial is expected to be dosed in 2023.
https://finance.yahoo.com/news/hookipa-pharma-achieves-5-million-120000230.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.